- Home
- NFJ vs CDNA Comparison
NFJ vs CDNA Comparison
Compare NFJ & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- CDNA
- Stock Information
- Founded
- NFJ 2005
- CDNA 1998
- Country
- NFJ United States
- CDNA United States
- Employees
- NFJ N/A
- CDNA N/A
- Industry
- NFJ Finance: Consumer Services
- CDNA Medical Specialities
- Sector
- NFJ Finance
- CDNA Health Care
- Exchange
- NFJ Nasdaq
- CDNA Nasdaq
- Market Cap
- NFJ 1.2B
- CDNA 1.1B
- IPO Year
- NFJ N/A
- CDNA 2014
- Fundamental
- Price
- NFJ $12.14
- CDNA $17.75
- Analyst Decision
- NFJ
- CDNA Buy
- Analyst Count
- NFJ 0
- CDNA 8
- Target Price
- NFJ N/A
- CDNA $29.43
- AVG Volume (30 Days)
- NFJ 223.5K
- CDNA 673.3K
- Earning Date
- NFJ 01-01-0001
- CDNA 05-08-2025
- Dividend Yield
- NFJ 9.01%
- CDNA N/A
- EPS Growth
- NFJ N/A
- CDNA N/A
- EPS
- NFJ N/A
- CDNA 0.93
- Revenue
- NFJ N/A
- CDNA $333,785,000.00
- Revenue This Year
- NFJ N/A
- CDNA $13.32
- Revenue Next Year
- NFJ N/A
- CDNA $14.99
- P/E Ratio
- NFJ N/A
- CDNA $19.11
- Revenue Growth
- NFJ N/A
- CDNA 19.07
- 52 Week Low
- NFJ $10.45
- CDNA $7.42
- 52 Week High
- NFJ $12.86
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- NFJ 40.29
- CDNA 37.14
- Support Level
- NFJ $12.07
- CDNA $18.16
- Resistance Level
- NFJ $12.26
- CDNA $20.00
- Average True Range (ATR)
- NFJ 0.15
- CDNA 0.83
- MACD
- NFJ 0.01
- CDNA 0.02
- Stochastic Oscillator
- NFJ 50.34
- CDNA 23.73
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. Its primary investment objective is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.